Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592991 | 0.85 | — | — | |
| SCHEMBL576472 | 0.85 | — | — | |
| SCHEMBL2080428 | 0.77 | CA1 (0.41) | CA1CA9SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL19460543 | 0.74 | CA1 (0.39) | CA1CA9SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5685516 | 0.74 | CA1 (0.34) | CA1CA9CA2CA4SMN1; SMN2 | |
| SCHEMBL20582783 | 0.74 | CA1 (0.39) | CA1CA9SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10593232 | 0.74 | CA1 (0.34) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL13515396 | 0.72 | — | — | |
| SCHEMBL5936327 | 0.72 | — | — | |
| SCHEMBL5936338 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345954-B1 | POLYROTAXANE, PRODUCTION METHOD THEREFOR, AND OPTICAL COMPOSITION CONTAINING SAID POLYROTAXANE | TOKUYAMA CORP (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-11578174-B2 | Polyrotaxane, production method therefor, and optical composition containing said polyrotaxane | TOKUYAMA CORPORATION (JP) | 2023-02-14 | — | — | US | disclosed |
| US-20200071467-A1 | Polyrotaxane, Production Method Therefor, and Optical Composition Containing said Polyrotaxane | TOKUYAMA CORPORATION (JP) | 2020-03-05 | — | — | US | disclosed |
| US-20180312643-A1 | Polyrotaxane, Production Method Therefor, and Optical Composition Containing said Polyrotaxane | TOKUYAMA CORPORATION (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3345954-A1 | POLYROTAXANE, PRODUCTION METHOD THEREFOR, AND OPTICAL COMPOSITION CONTAINING SAID POLYROTAXANE | Tokuyama Corporation (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9090629-B2 | Cytotoxic agents comprising new ansamitocin derivatives | IMMUNOGEN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090629-B2 | Cytotoxic agents comprising new ansamitocin derivatives | IMMUNOGEN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2792372-A1 | BIODEGRADABLE MEDICAL ADHESIVE AND PREPARATION METHOD AND USE THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2014-10-22 | — | — | EP | disclosed |
| US-20130323268-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2635301-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | ImmunoGen, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061590-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323268-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | MLNR, ANXA6, ANXA4 | CA1 1865/4885CA9 2169/4885CA2 2984/4885 |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | MLNR, ANXA6, ANXA4 | CA1 1865/4885CA9 2169/4885CA2 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.